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Background: In vitro data suggest that panobinostat (LBH589), a 
pan-deacetylase inhibitor, may add therapeutic benefit in the treat-
ment of small-cell lung cancer (SCLC) with regression of tumors. 
Methods: This multicenter, nonrandomized phase 2 trial was 
designed to evaluate antitumor activity of LBH589 in patients with 
previously treated SCLC. Patients received LBH589 administered 
intravenously at a dose of 20 mg/mq (days 1–8) every 21 days. 
Results: A total of 21 patients with extensive- or limited-stage 
SCLC were enrolled. Patients received a median of two cycles 
(range, 1–6). LBH589 was well tolerated, and the most common 
toxicities were grade 1 to 2 gastrointestinal disorders (nausea 38%, 
diarrhea 24%, vomiting 19%), grade 1 to 2 thrombocytopenia 
(14.3%). Of 19 patients evaluable for efficacy, two cases showed 
shrinkages more than 30% at first assessment, with time to progres-
sion of 14 and 21 weeks, respectively, and there were three long 
disease stabilizations of 12, 10, and 13 weeks. The study was pre-
maturely closed because of a lack of activity.
Conclusion: This is the first report of a pan-deacetylase inhibitor 
inducing tumor shrinkage and sustained stable disease in SCLC. We 
believe that although the trial was prematurely discontinued, modest 
clinical activity of LBH589 combined with a favorable safety profile 
in pretreated SCLC patients was observed, which warrants further 
exploration of the potential contribution of LBH589 in other trials.
Key Words: Panobinostat, LBH58, Small-cell lung cancer, Phase II 
trial, Deacetylase inhibitor.
(J Thorac Oncol. 2013;8: 1091-1094)
Small-cell lung cancer (SCLC) is the most aggressive and lethal form of lung cancer, and is associated with a high 
incidence of tumor relapse and very poor life expectancy.1 
Current management usually consists of combination 
chemotherapy regimens based on cisplatin or carboplatin and 
etoposide,2 with a median overall survival of approximately 
10.2 months.3 Despite the high response rate (RR), 
approximately 80% of patients with limited disease and nearly 
all patients with extended disease develop disease progression. 
Topotecan is at present the only agent approved for second-line 
treatment of SCLC patients. However, activity particularly in 
refractory patients is very modest, with a time to progression 
of 13 weeks, and a median overall survival of 25 weeks.4,5 The 
research of a new therapeutic agent that is able to improve the 
natural history of SCLC would be an important goal to achieve. 
Deacetylases (DACs) are enzymes that remove the acetyl 
groups from histones, the core proteins in chromatin around 
which DNA is wrapped. For this reason, these enzymes are 
often referred to as histone deacetylases (HDACs).6 Histone 
proteins are implicated in epigenetic modifications, which 
could cause decrease of tumor suppressor gene activity (p21, 
p27)7 with a progression of cell growth that is associated with 
down-regulation of the cyclin-dependent kinase inhibitors. 
This shows a crucial, nonredundant role for HDACs in 
regulating cell proliferation. The second major target for 
DACs are nonhistone proteins, like tumor-suppressor protein 
p53, α-tubulin, hypoxia inducible factor-1α, and heat-shock 
protein,8,9 which have been shown to modulate cancer cell 
growth and survival pathways. A pan-DAC inhibitor can target 
all classes of DACs, thereby modulating histone and nonhistone 
proteins implicated in oncogenesis and ultimately interfering 
with multiple hallmarks of cancer.7 Panobinostat (LBH589) is 
a novel hydroxamate analog pan-DAC inhibitor available for 
intravenous and oral administration. LBH589 has been shown 
to inhibit purified HDAC enzyme in vitro and in vivo, causing 
an increase of histone H3 and H4 acetylation levels, and to 
produce p21 activation as a consequence of the inhibition of 
nonhistone protein.10 Preclinical data showed high sensitivity 
of SCLC cells lines to LBH589,11 and in transgenic mice 
experiments induced almost complete regression of the tumors 
at tolerable dosages.10 Two studies analyzed combinations of 
LBH589 and cytotoxic agents in SCLC cell lines and xenograft 
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models. Concentrations of the DNA methyltransferase inhibitor 
decitabine (5-AZA-dC) and the HDAC inhibitors (LBH589) 
synergistically reduced the proliferation of five of nine SCLC 
cell lines.12 LBH589 was, however, particularly effective in 
SCLC xenografts, and the addition of the chemotherapy agent 
etoposide augmented antitumor effects.13 The high activity of 
LBH589 in SCLC cell lines together with preliminary clinical 
data give the rationale to test this drug in this disease.
PATIENTS AND METHODS
Study Population
The eligibility criteria for patients included were: histo-
logical or cytological diagnosis of SCLC; age less than 75 years; 
two or lesser prior chemotherapy lines; progression after and 
not during last chemotherapy treatment (platinum-refractory 
patients were excluded); measurable disease as defined by 
Response Evaluation Criteria in Solid Tumor, (RECIST) version 
1.0;14 Eastern Cooperative Oncology Group performance status 
of 0 to 1; life expectancy of at least 3 months; adequate hema-
tological (hemoglobin ≥ 9 g/dl; platelet count ≥ 100,000/mm3; 
neutrophils count ≥ 1500/mm3), liver (serum bilirubin ≤ 1.5 × 
aspartate aminotransferase and alanine aminotransferase ≤ 2.5 
× upper normal limit (UNL) or ≤ 5.0 × UNL if the transaminase 
elevation is because of hepatic involvement, albumin ≥ 2.5 g/dl, 
alkaline phosphatase ≤ 2.5 × UNL), and renal functions (total 
UNL; serum creatinine ≤ 1.5 × UNL or 24-hour creatinine clear-
ance ≥ 50 ml/minutes).
The protocol was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice guide-
lines. The study was approved by the ethics committee of each 
participating institution, and written informed consent was 
obtained from each patient before inclusion.
Study Design and Treatment
This was a multicenter, international, open-label, non-
randomized phase 2 trial, designed to evaluate antitumor 
activity of LBH589 in patients with SCLC. The ClinicalTrials.
Government Identifier: NCT01222936. LBH589 was admin-
istered as a 30-minute intravenous infusion at a dosage of 
20 mg/m2, on days 1 and 8, every 21 days.
Clinical examination was performed before every cycle. 
Complete blood cell count was performed weekly. Twelve-
lead electrocardiograph (ECG) assessments were performed 
at screening preinfusion, 4 and 24 hours after infusion, and 
on day 8. Evaluation of the disease was organized every 6 
weeks (2 cycles) by computed tomography sca,n according to 
RECIST (version 1.0). Toxicity was determined according to 
the National Cancer Institute Common Toxicity Criteria (ver-
sion 3.0).15 Prophylactic antiemetic measures before adminis-
tration of infusion, loperamide as initial therapy of diarrhea, 
and recombinant hematopoietic growth factors were allowed 
during treatment at the discretion of investigators.
Patients were taken off study in case treatment recycling 
was delayed by more than 2 weeks, occurrence of unaccept-
able adverse events (AE), protocol violation, or noncompli-
ance with study protocol. Dosage was modified at next cycle 
to 15 and 10 mg/m2 after recovery to grade 1 toxicity in case 
of: grade 4 hematological toxicity, febrile neutropenia, car-
diac toxicity defined as multiple QTcF higher than 480 but 
less than 500 msec (determined by more ECGs), or any QTc 
higher than or equal to 500 but less than 515 msec; grade 3 
or 4 nonhematological toxicity. Treatment was administered 
till patient’s progression. LBH589 was given by Novartis in 
accordance with the ethical principles, which have their origin 
in the Declaration of Helsinki and are consistent with Good 
Clinical Practice, and the applicable regulatory requirements.
Statistics
The primary endpoint was the RR. Secondary endpoints 
included characterization of toxicities, duration of response, 
and time to progression.
A Simon’s two-step optimal design was used to assess 
the primary endpoint, assuming an unacceptable RR of 7%, 
and an acceptable rate of 20% on a sample of 48 evaluable 
patients, with a type I error of 1.0 and a power of 0.85.16
Accrual was terminated if less than two objective 
responses were achieved on the first 17 evaluable patients. If 
at the end of the trial less than five responses were achieved, 
no further investigation was warranted.
RESULTS
Between May 2008 and April 2009, a total of 21 
patients with progressed SCLC were enrolled in the study. 
TABLE 1.  Patients Characteristics
Patients Characteristics (N = 21)
Demographics
 Age (yr) median (range) 62 (47–75)
 Men/women 12/9 (57%–43%)
ECOG PS
 0 9 (42.9%)
 1 12 (57.1%)
Stage at study entry
 Extensive 12 (57.1%)
 Limited 7 (33.3%)
 Not evaluable 2 (9.5%)
Progression disease status
 Sensiblea 14 (66.6%)
 Resistantb 7 (33.3%)
Prior therapy
 Radiotherapy 18 (85.7%)
 Surgery 3 (14.3%)
 Prior systemic therapy (Metastatic/recurrent disease) 21 (100%)
 Prior chemotherapy for metastatic diseasec 20 (95.2%)
 First-line 13 (61.9 %)
 Second-line 7 (33.3 %)
aProgression of disease >90 days from previous treatment.
bProgression of disease <90 days from previous treatment.
cEach prior systemic chemotherapy for metastatic disease after which patient 
progressed is counted as first-line. Prior systemic chemotherapy for metastatic disease 
administered in absence of PD are not counted as new-line. One patient received prior 
chemotherapies and started study treatment without PD.
ECOG, Eastern Coopeartive Oncology Group; PS, performance status; PD, 
progressive disease.
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Patients characteristics are shown in Table 1. The percentage 
of patients who had extensive disease was 57.1%, and 33.3% 
were resistant to previous treatment. All patients entered in the 
study were treated with LBH589 and received total number of 
49 cycles, with a median number of two cycles (range, 1–6).
Overall compliance was good, and reduction of dosage was 
done in 12 of 49 cycles because of AEs. Mean relative dos-
age intensity was 87.6% of the planned dosage. Even though 
the trial was prematurely closed at the end of step 1 in the 
absence of RECIST-defined partial responses (PRs), this is the 
first study that showed some signal activity of DAC in SCLC.
Toxicity
LBH589 was generally well tolerated; the most 
common toxicities were grade 1 to 2 gastrointestinal disorders 
(nausea 38%; diarrhea 24%; vomiting 19%) and grade 1 to 
2 thrombocytopenia (14.3%). One patient experienced grade 
3 hypertension, which was not drug related. Among the 15 
patients experiencing treatment-related AE, six had a grade 3 
or higher treatment-related AEs; no treatment-related serious 
adverse events occurred. Among the 122 ECGs analyzed, there 
was no QTc greater than 480 msec increased from baseline 
(with exception of a slight increase in one patient). There was 
no neccesity for dosage reduction or discontinuation because 
of cardiac toxicity. The most significant drug-related AEs are 
shown in Table 2.
Response
In the 19 patients evaluable for efficacy, we observed 
shrinkages of more than 30% in two cases at first assessment 
(week 6), which did not qualify for PR at week 12 because of the 
appearance of a new lesion in first case, and reduced shrinkage 
(19% stable disease [SD]) in the second case (time to progression 
14 and 21 weeks) and also obtained three long-lasting disease 
stabilizations of 12, 10, 13 weeks (time on study and response are 
shown in Fig. 1). Accrual was terminated if less than two objec-
tive responses were achieved on the first 17 evaluable patients. 
To summarize, five patients (26.3%) achieved SD, 14 
patients (73.6%) progressive disease (PD), and two patients 
TABLE 2.  Most Significant Drug-Related Adverse Events
Toxicity Grade 1–2 N (%) Grade 3 N (%)
Hematological
 Thrombocytopenia 3 (14.3) —
 Anemia 3 (14.3) —
 Blood alkaline phosphatase increased 1 (4.8) —
Nonhematological
 Asthenia 2 (9.5) 1(4.7)
 Fatigue 3 (14.3) —
 Diarrhea 5 (23.8) —
 Nausea 8 (38.1) —
 Vomiting 4 (19) —
 Constipation 2 (9.5) —
FIgURE 1.  Time on study and response. SD, standard deviation.
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(10, 5%) were not evaluable for response because of early 
withdrawal from the study because of disease-related events 
(cardiac and respiratory insufficiency leading to death 19 
days after the enrollment and to asthenia G3). Two patients 
with a PR at 6 weeks were resistant (PD < 90 days) to 
previous treatment.
Median time to progression was only 1.41 months 
(95% confidence interval: 1.3–2.2). Median duration of SD 
was 3 months (95% confidence interval: 2.3–4.9).
DISCUSSION AND CONCLUSION
Several drugs have been evaluated in SCLC second-line 
treatment, but without success. Recent progress in the under-
standing of the biology of SCLC has led to the identification 
of crucial signaling pathways and the subsequent development 
of targeted therapies. Several novel molecules are presently 
undergoing evaluation; in this trial, a pan-HDAC inhibitor 
LBH589 showed modest activity in SCLC. LBH589 is a pan-
HDAC inhibitor that has demonstrated preclinical anticancer 
effects in non–small-cell lung cancer and SCLC models; this 
agent was also tested in non–small-cell lung cancer patients 
in a phase I trial in combination with erlotinib.17Disease sta-
bilization could be considered a clinically relevant result in 
patients affected by SCLC in second-line setting.18 In this 
patient population, SD and PR were associated with a survival 
benefit versus PD; interestingly, the survival benefit was simi-
lar between the two groups (PR and SD). These results suggest 
that at least in these populations, SD may represent a poten-
tial benefit of chemotherapy, and therefore, the distinction 
between SD and PR may not be useful. LBH589 monother-
apy is well tolerated in patients and has modest single-agent 
activity, even if there were no complete or partial responses. 
The potential contribution of LBH589, in combination with 
standard cytotoxic regimens, should be investigated, given the 
results obtained in preclinal studies.
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